AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will present an overview followed by a fireside chat with Dr. Pamela Palmer on March 24, 2021, at the Benzinga Biotech Small Cap Conference. The presentation starts at 9:25 AM EST and the chat at 11:35 AM EST. Interested participants can register online. A replay will be available for 90 days in the investor relations section of AcelRx's website. The company focuses on developing innovative therapies for medically supervised settings, with one approved product in the U.S. and one investigational product.
- AcelRx has one approved product, DSUVIA, in the U.S. and DZUVEO in Europe.
- The company's investigational product, Zalviso, is designed for patient-controlled analgesia in medically supervised settings.
- None.
REDWOOD CITY, Calif., March 22, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced that management will present an overview of AcelRx Pharmaceuticals, followed by a fireside chat with Dr. Pamela Palmer. The presentation will take place on March 24, 2021 at 9:25 AM EST / 6:25 AM PST, and the fireside chat will begin at 11:35 AM EST / 8:35 AM PST.
Individuals interested in attending the live events can register here https://www.benzinga.com/events/small-cap/biotech/. A replay of the Company's presentation and fireside chat will be available online in the investor relations section of the Company's website for 90 days following the events.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.
For additional information about AcelRx, please visit www.acelrx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-announces-presentation-and-fireside-chat-at-the-benzinga-biotech-small-cap-conference-301253108.html
SOURCE AcelRx Pharmaceuticals, Inc.
FAQ
What is AcelRx Pharmaceuticals announcing on March 24, 2021?
Who will be speaking at AcelRx's presentation on March 24, 2021?
Where can I find the replay of AcelRx's March 24, 2021 presentation?
What products does AcelRx Pharmaceuticals currently have?
